Mesenchymal Stem Cells Therapy for Intrauterine Adhesions and Endometriosis: Potential, Mechanisms, and Future Directions
The FASEB Journal · 30.06.2026 · 40 (12)
DOI: 10.1096/fj.202504018rr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 13.06.2026. Verfasst von Si-Han Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China. Hauptthemen laut MEDLINE: Endometriosis, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Uterine Diseases. Die Arbeit nennt 89 Literaturangaben.
Abstract (Originalsprache)
Intrauterine adhesions (IUA) and endometriosis are debilitating gynecological disorders that impair endometrial function and fertility. IUA, typically caused by iatrogenic trauma to the basal endometrium, leads to fibrosis and infertility, whereas endometriosis, characterized by ectopic endometrial growth, induces chronic inflammation, pain, and subfertility. Current treatments, such as surgical adhesiolysis for IUA and hormonal suppression for endometriosis, frequently fail to address underlying pathological mechanisms, including aberrant fibrosis, inflammatory cascades, and impaired tissue regeneration. Recently, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic approach. Their therapeutic benefits are mediated primarily through paracrine actions, which modulate immune responses, promote tissue repair, and attenuate inflammation and fibrosis. Recent studies have further highlighted the potential of MSC‐derived exosomes (MSC‐Exos) as a cell‐free alternative. In this review, we comprehensively summarize current evidence from animal models and clinical studies on the application of MSCs and MSC‐Exos in treating IUA and endometriosis, focusing on their therapeutic potential, mechanisms of action, and future directions. We also discuss remaining challenges and promising strategies to overcome them, thereby positioning MSC‐based therapies as transformative options for endometrial restoration and disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Huankui Academy, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Queen Marry College, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- Department of Obstetrics and Gynecology, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
- School of Science, East China University of Technology, Fuzhou, P. R. China.
ORCID-Profile: Quan-Wen Liu
Zitieren
APA
Liu, S. H., He, S. Y., Ji, B. Q., Zhang, X. C., Li, J. Y., & Liu, Q. W. (2026). Mesenchymal Stem Cells Therapy for Intrauterine Adhesions and Endometriosis: Potential, Mechanisms, and Future Directions. The FASEB Journal, 40(12). https://doi.org/10.1096/fj.202504018rr
Vancouver
Liu SH, He SY, Ji BQ, Zhang XC, Li JY, Liu QW. Mesenchymal Stem Cells Therapy for Intrauterine Adhesions and Endometriosis: Potential, Mechanisms, and Future Directions. The FASEB Journal. 2026;40(12). doi:10.1096/fj.202504018rr
BibTeX
@article{Liu2026,
author = {Liu, Si-Han and He, Shu-Yang and Ji, Bing-Qian and Zhang, Xiang-Cheng and Li, Jing-Yuan and Liu, Quan-Wen},
title = {Mesenchymal Stem Cells Therapy for Intrauterine Adhesions and Endometriosis: Potential, Mechanisms, and Future Directions},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {12},
doi = {10.1096/fj.202504018rr}
}
EUVIMED